‘The very factors that drive the success of the generic market in the UK may be under threat’
Future of Pharmaceuticals 2019
It takes an average of 10-15 years to get a drug to market, but how will artificial intelligence make a difference in the early development stages of drugs? Our Future of Pharmaceuticals special report, published in The Times, explores how the industry is moving to be part of open, learning communities where collaboration is at the forefront. It examines why pharmaceuticals is lagging behind in exploiting technological possibilities and whether we should redefine ageing as a disease. It looks at antimicrobial resistance and what antibiotics are really worth. Also featured is an infographic analysing the global rise of generic drugs.
Please register to download
Please register to download this report. Registration is 100% free and provides access to all the latest insight and analysis shaping business today.
In association with
In this report
Strategic use of patient data is signalling a bright future for drug development in the face of unprecedented global healthcare challenges
Innovative use of transformative big data can bring medicines to those in need, improve healthcare systems and empower patients
An innovative pharma company has set its sights on treating non-viral liver diseases
Industry leaders hold the “magic wand” to empower their talent to supercharge the potential of a patient-centric pharma value chain, says Louis Hendriks, founder and initiator of Global Value Web
As the era of blockbuster drugs comes to an end, pharma is moving towards drugs that are increasingly complex and made for small patient populations, creating opportunities and challenges for contract development and manufacturing organisations (CDMOs)